| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 11/4/264:00 PM | -$0.34 | $0.50GAAP | +247% | +725% | $63.6M | $116.5M | +83.3% | +455% | |
| Q2 '26 | 8/5/264:00 PM | -$0.83 | -$0.29GAAP | +65.1% | +29% | $17.2M | $51.2M | ⚠ Check | +17% | |
| Q1 '26 | 5/6/264:01 PM | -$0.73 | -$1.71GAAP | -134% | -159% | $25.0M | $4.5M | ⚠ Check | -86% | |
| Q4 '25 | 2/25/264:01 PM | -$0.61 | -$0.09GAAP | +85.2% | +85% | $26.6M | $28.2M | +5.9% | -47% | |
| Q3 '25 | 11/5/254:01 PM | -$0.71 | -$0.08GAAP | +88.7% | +89% | $27.5M | $21.0M | -23.6% | +96% | |
| Q2 '25 | 8/6/254:00 PM | -$0.74 | -$0.41GAAP | +44.6% | +62% | $21.6M | $43.6M | +102% | +157% | |
| Q1 '25 | 5/7/254:00 PM | -$0.57 | -$0.66GAAP | -15.8% | +41% | $23.4M | $32.7M | +39.6% | +156% |
⚠ Potential error in calculation, check manually. The two revenue figures may be in different units or currencies.
GAAP = diluted EPS as filed with the SEC.